Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall, Johann S. de Bono(Royal Marsden NHS Foundation Trust), George Seed(Institute of Cancer Research), Pasquale Rescigno(Royal Marsden NHS Foundation Trust), Wei Yuan(Chinese Academy of Medical Sciences & Peking Union Medical College), Gunther Boysen, Raquel Pérez-López(Royal Marsden NHS Foundation Trust), David Dolling(Institute of Cancer Research), Matthew Clarke(Institute of Cancer Research), Joaquı́n Mateo(Hebron University), Helen Mossop, Mateus Crespo(Institute of Cancer Research), Berni Ebbs(Institute of Cancer Research), Nina Tunariu(Leicester Royal Infirmary), Emma Hall(The Royal Wolverhampton NHS Trust), Gemma Fowler, Susana Miranda(Royal Marsden NHS Foundation Trust), Shahneen Sandhu(Peter MacCallum Cancer Centre), Ruth Riisnaes(Institute of Cancer Research), Mark Atkin(Institute of Cancer Research), Penny Flohr(Royal Marsden NHS Foundation Trust), Adam Sharp(Institute of Cancer Research), Núria Porta, Dan R. Robinson(University of Michigan), Daniel Nava Rodrigues(Royal Marsden NHS Foundation Trust), Zafeiris Zafeiriou(Royal Marsden NHS Foundation Trust), Alexa Gillman, Suzanne Carreira(Institute of Cancer Research), Christopher J. Lord(Institute of Cancer Research), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Ines Figueiredo(Institute of Cancer Research), Cláudia Bertan(Institute of Cancer Research), Arul M. Chinnaiyan(Howard Hughes Medical Institute), Semini Sumanasuriya(Institute of Cancer Research)
Cited by 422
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k